AveXis to Present at the 26th Annual Piper Jaffray Healthcare Conference

Dallas, TX, November 21, 2014 --(PR.com)-- AveXis, a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases like Spinal Muscular Atrophy, today announced that Mr. John Carbona, Chief Executive Officer, and Dr. Brian Kaspar will present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014. AveXis will present at 1:50 p.m. EDT in the Kennedy 2 room on the fourth floor at The New York Palace, New York, New York.

This year’s conference will feature more than 250 of the most highly regarded and influential companies in the biotechnology, specialty pharmaceuticals, medical technology, medical diagnostics, life science tools and healthcare services sectors. Industry experts, physicians and academicians will participate on panel discussions addressing increasingly complex regulatory, reimbursement and legal issues. The conference will also feature discussions on the largest, most costly disease states.

About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. SMA is caused by a genetic defect in the SMN1 gene which codes SMN, a protein necessary for survival of motor neurons. SMA kills more infants than any other genetic disease in today's world.

About AveXis
Based in Dallas, Texas, AveXis is a clinical stage gene therapy platform company establishing unique industry alliances to create innovative treatments for people with unmet medical needs. Spinal muscular atrophy (SMA) is the company’s first focus. For more information regarding AveXis, please visit www.avexisinc.com